United States Dilated Cardiomyopathy Market Insight
Published: 18 May 2026 | Report Format: Electronic (PDF)
US dilated cardiomyopathy market size is growing at a 7.2% CAGR, driven by increasing prevalence of cardiovascular diseases, rising awareness of early diagnosis, and advancements in targeted therapies and precision medicine.
U.S. Dilated Cardiomyopathy Market Insights Forecasts to 2035
- The US Dilated Cardiomyopathy Market Size Was Estimated at USD 0.36 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 7.2% from 2025 to 2035
- The US Dilated Cardiomyopathy Market Size is Expected to Reach USD 0.72 Billion by 2035
Notable Insights for U.S. Dilated Cardiomyopathy Market
- By service type, the pharmacological treatment segment dominated the market, generating approximately USD 0.21 billion in revenue in 2024.
- By application, the hospital treatment segment is expected to witness the fastest growth, supported by increasing hospitalization rates and demand for advanced cardiac care.
- Approximately 52% of diagnosed cases globally are reported in the US, while nearly 60% of patients rely on ACE inhibitors, beta-blockers, and ARBs for disease management, enhancing treatment demand. Additionally, North America holds over 40% share of the global dilated cardiomyopathy market, reflecting strong healthcare infrastructure.
- Increasing adoption of precision medicine and genetic testing is strengthening the US dilated cardiomyopathy market, as targeted therapies and personalized treatment approaches improve patient outcomes and disease management.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the US Dilated Cardiomyopathy market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United States Dilated Cardiomyopathy Market
- Bristol Myers Squibb
- Berlin Cures
- Cumberland Pharmaceuticals
- Rocket Pharmaceuticals
- Solid Biosciences
- Amgen Inc.
- Novartis AG
- AstraZeneca plc
- Others
Recent Developments:
- In April 2026, Rocket Pharmaceuticals advanced its gene therapy candidate for dilated cardiomyopathy into late-stage clinical development in the US, focusing on improving cardiac function and addressing genetic causes of the disease.
- In July 2024, Bristol Myers Squibb expanded clinical research for novel cardiac myosin activators, aiming to enhance myocardial contractility and improve treatment outcomes for patients with dilated cardiomyopathy.
Market Segmentation:
United States Dilated Cardiomyopathy Market, By Product Type
- Pharmacological Treatment
- Device Therapy
- Gene Therapy
United States Dilated Cardiomyopathy Market, By Application
- Hospitals
- Specialty Clinics
- Ambulatory Care
United States Dilated Cardiomyopathy Market, By End User
- Adults
- Pediatric
- Geriatric
Expert Views:
The US dilated cardiomyopathy market will experience continuous growth because of increasing cardiovascular diseases and better treatment innovations. The experts predict that hospitals will use two main types of treatment, which include medicines and their current hospital methods, while new advancements in gene therapy, precision treatment and new drugs will create better patient results and keep the market growing for an extended period.